Evotec CEO Christian Wojczewski (L) and Halozyme CEO Helen Torley
November 15, 2024 07:16 AM ESTUpdated 07:57 AM
Deals
Manufacturing

Evotec gains on Halozyme's takeover pro­pos­al

Kyle LaHucik

Senior Reporter

Halozyme said Thurs­day post-mar­ket that it wants to buy Evotec for €11 per share in cash, giv­ing the strug­gling drug dis­cov­er­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Eli Lil­ly sues the US gov­ern­ment over its pro­posed 340B re­bate mod­el

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times